A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck.

本研究为一项多中心、开放标签的剂量探索与剂量扩展临床试验，旨在评估MEDI4736联合曲美木单抗（tremelimumab）治疗复发/转移性头颈部鳞状细胞癌受试者的安全性、耐受性、抗肿瘤活性、药代动力学（PK）、药效动力学（pharmacodynamics）及免疫原性。